ARAvner Reshef

Avner Reshef

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avner Reshef has a total of 303 co-authors. Here are the top co-authors by number of shared publications:

  • Iris Leibovich-Nassi

    Barzilai Academic School of Nursing Barzilai University Medical Center Ashkelon Israel

    6 shared publications
  • Andrea Zanichelli

    Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato Milan Italy

    4 shared publications
  • Anete S. Grumach

    Clinical Immunology, Centro Universitario Faculdade de Medicina do ABC Santo Andre Brazil

    4 shared publications
  • Grzegorz Porebski

    Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland

    4 shared publications
  • Teresa Caballero

    Department of Allergy Hospital Universitario La Paz, Hospital La Paz Health Research Institute (IdiPAZ), biomedical Research Network on Rare Diseases (CIBERER, U754) Madrid Spain

    4 shared publications
  • Timothy Craig

    Department of Pediatrics, Pennsylvania State University, Hershey, Pennsylvania, USA

    4 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema

    by Henriette Farkas, Inmaculada Martinez‐Saguer, Konrad Bork, Anastasios E. Germenis, Anete S. Grumach, Hanga Réka Horváth, Andrea Luczay, Andrea Zanichelli, Markus Magerl, Stephen Betschel, et al.

    Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disease characterized by unpredictable episodes of tissue swelling (angioedema), which, in most cases, occur first under the age of 18 years, and entail a significant burden of disease not only for the patients but also for their families. Clinical symptoms of HAE are not specific, which may cause difficulties in differential diagnosis. Additionally, if not appropriately treated, HAE attacks can be life‐threatening. The international HAE guidelines published so far have focused mainly on adults. A guideline that refers to the age‐specific characteristics of pediatric patients, both in terms of diagnosis and management, was therefore needed. The International Steering Committee and Taskforce developed recommendations and provided evidence‐based grading based on expert opinion and strength of evidence. Recommendations were presented to, discussed, and electronically voted by healthcare professionals during the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary, 2025. This international guideline will ensure early diagnosis, standardized and up‐to‐date treatment, and promote the availability of effective therapies for all pediatric patients affected with this rare disease. It also draws attention to the importance of establishing HAE centers and registries, which solicit specialist care and research of the disease.


  • Open Access

    Clinical Expressions, Disease Course, Quality of Life, and Resilience in Subgroups of Patients with Angioedema

    by Iris Leibovich-Nassi, Avner Reshef, Michal Itzhaki

    Background: Patients with angioedema experience recurrent attacks of unpredictable swelling. Recently, new genetic variants have been identified, while patients with unknown causes and no identifiable genetic mutations represent a separate subgroup. As a lifelong illness, angioedema significantly impacts the patient’s quality of life and coping ability. Comparing patients representing different subgroups of angioedema is an unmet need. Methods: A cross-sectional, prospective study was conducted to analyze three angioedema subgroups: A: HAE-C1 INH (Types 1 & 2), B: HAE-FXII, and C: AE-UNK; employing validated questionnaires. Results: The study included 111 patients with a mean age of 44.51 years. Mean age of onset was 16.1 years, and mean age at diagnosis was 19.58 years. Subgroups A, B, and C consisted of 72 (64%), 16 (14%), and 23 (20%) patients, respectively. Mean age of onset was earlier in A (10.31 years) than in B (19.70) and C (30.34) subgroups (p < .001). Similarly, mean age at diagnosis was earlier in A (13.85 years) compared to B (24.93) and C (34.73) subgroups (p < .001). Significant differences were found in the triggers of attacks, but not in the body location of the attacks or in experiencing pre-attack prodromes. Subgroup A reported the highest coping ability (p < .001) and total resilience scores (p < .001), mainly in emotion regulation and attention under stress. Conclusions: The designated subgroups differ in both clinical course and coping aptitude. Recognizing the unique characteristics of each AE subgroup can improve the management and quality of life of patients with this lifelong and rare disease.

  • Open Access

    Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study

    by Avner Reshef, Connie Hsu, Constance H. Katelaris, Philip H. Li, Markus Magerl, Keiko Yamagami, Mar Guilarte, Paul K. Keith, Jonathan A. Bernstein, John‐Philip Lawo, et al.

    Background: Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long‐term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open‐label extension (OLE) study evaluating the long‐term safety and efficacy of garadacimab for HAE prophylaxis.Methods: Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment‐emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.Results: At data cut‐off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9–16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient‐year. Garadacimab‐related TEAEs (13% of patients, 52 events) were most commonly injection‐site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab‐related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID‐19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run‐in period; 60% of patients were attack‐free. Almost all patients (93%) rated their response to garadacimab as “good” or “excellent.”Conclusion: Garadacimab has a favorable safety profile suitable for long‐term use and provides durable protection against HAE attacks.


  • Top Cited Papers

    Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

    by Avner Reshef, Thomas Buttgereit, Stephen D. Betschel, Teresa Caballero, Henriette Farkas, Anete S. Grumach, Michihiro Hide, Ankur K. Jindal, Hilary Longhurst, Jonathan Peter, et al.


  • Open Access

    Prodromes predict attacks of hereditary angioedema: Results of a prospective study

    by Iris Leibovich‐Nassi, Hava Golander, Avner Reshef


  • Open Access

    Prodromes predict attacks of Hereditary Angioedema: results of a prospective Study

    by Avner Reshef, Iris Leibovich-Nassi, Hava Golander

    Background: Prodromes are signs and symptoms preceding attacks. Many Hereditary Angioedema patients are able to foretell the onset of attacks by having a prodrome. However, the clinical significance and practical value of prodromes as predictors of attacks needs to be assessed by objective measures. Objective: To prospectively evaluate associations between prodromes and attacks. Methods: 48 patients reported four occasions of prodromes, attacks or both. Pre-defined domains and scalable dimensions were assessed in each episode by a disease-specific instrument. Results: Participants reported 192 different events. Significant differences were found across all dimensions, indicating that prodromes are distinct from attacks. Positive correlations were found between the same attributes of prodromes and attacks. Specifically, pain was correlated in the extremities (r = .291, p < .05) and oropharyngeal clusters (r = .936, p < .01). Impairment was correlated across all clusters, most notably in the abdomen (r = .288, p < .05) and face (r = .588, p < .05) clusters. Dysfunction correlated for the abdomen (r = .366, p < .01), facial (r = .882, p < .01), extremities (r = .381, p < .05) and oropharyngeal (r = .790, p < .05) clusters. Experiencing a prodrome is associated with higher risk of attack in the abdomen (RR=2.30), urogenital (RR=16.39), facial (RR=2.94), extremities (RR=5.55) and oropharyngeal (RR=33.31) locations. Conclusions: Prodromes can be distinguished from attacks. Most patients with prodrome had subsequent attack, and their clinical features correlated in certain body locations. Experiencing prodromal signs and symptoms increase likelihood of having an attack.

  • Top Cited Papers
    Open Access

    The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

    by Marcus Maurer, Markus Magerl, Stephen Betschel, Werner Aberer, Ignacio J. Ansotegui, Emel Aygören‐Pürsün, Aleena Banerji, Noémi‐Anna Bara, Isabelle Boccon‐Gibod, Konrad Bork, et al.

    Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.


  • Prodromes as predictors of hereditary angioedema attacks

    by Iris Leibovich‐Nassi, Avner Reshef, Raz Somech, Hava Golander